Company news
Pioneering initiative will generate data at the frontier of healthcare to help transform early biological signals into new opportunities for prevention, diagnosis and treatment
Mayo Clinic today announced the launch of Precure LLC, with founding partner Thermo Fisher Scientific, to help transform how the life sciences community understands the biological changes that occur as people move from health toward disease.
Precure LLC will create one of the world’s leading biomedical datasets through one of the largest human multi-omics data-generation efforts, integrating proteomic, genomic and longitudinal clinical data to help researchers identify early biological signals of disease and provide a foundation for new discoveries in disease biology, diagnostics and therapeutics.
Many diseases begin developing biologically years before symptoms lead to a clinical diagnosis. By connecting molecular and clinical data over time, Precure LLC has the potential to help researchers better understand these early changes, accelerate drug development and create new opportunities for earlier diagnosis, intervention and more personalized care across a wide range of diseases, such as cancer, cardiometabolic disease, neurological disorders and immune-mediated disease.
Precure LLC will bring together molecular data generated from one million biospecimens, linked with longitudinal clinical information collected over several years, integrating genomic and proteomic information with Mayo Clinic’s clinical data and expertise in a highly standardized setting. Advanced AI and large-scale data-analytics will be integral to identifying patterns within these complex datasets and translating them into actionable insights. Mayo Clinic will be the majority owner of Precure LLC with Thermo Fisher joining the partnership as a minority owner.
“At Mayo Clinic, we are committed to transforming patient care through innovation,” says Dr. Gianrico Farrugia, president and CEO, Mayo Clinic.
“By harnessing the full potential of multi-omics data, Precure LLC aims to help us better understand disease before symptoms appear, accelerating discoveries that can lead to earlier diagnoses, more targeted treatments and better outcomes for patients,” he added.
Together, the organisations contribute complementary expertise designed to generate the molecular and clinical data needed to accelerate discovery and translate new insights into advancements in patient care:
“Precure LLC has the potential to create a step change in how we generate and apply multi-omics data to improve human health,” said Marc Casper, Chairman and CEO, Thermo Fisher Scientific.
“By combining Thermo Fisher’s leadership in scientific technology with Mayo Clinic’s leadership in clinical care, research and innovation, we can create new opportunities at unprecedented scale to detect disease earlier, accelerate drug development and enable more precise therapies,” he said.
Precure LLC complements Precure Research, Mayo Clinic’s investigator-led scientific effort to understand the biological changes that occur as people move from health toward disease. Precure Research advances the science of identifying and understanding early disease signals, while Precure LLC provides the scale, infrastructure and collaborations needed to generate population-scale molecular data and help translate discoveries into new diagnostics, therapeutics and other healthcare solutions. Mayo Clinic provides the pathway to validate discoveries and ultimately brings meaningful advances into patient care.
Mayo Clinic's involvement in Precure LLC is intended to advance its nonprofit mission. Any financial returns to Mayo Clinic would be reinvested in its mission of patient care, research and education.
Click here for more information.
Picture credit: Tony Webster from Minneapolis, Minnesota, USA. This image is licensed under the Creative Commons Attribution 2.0 Generic license
ILM 51.6 Sept 2026
Product directory
